Transaction in Own Shares

Summary by AI ^BETAClose X

Craneware plc has announced its participation in a share buyback program, purchasing a total of 177,435 ordinary shares between March 24 and March 30, 2026. The volume-weighted average purchase price across all transactions was approximately 1322.74 pence per share, with individual purchases ranging from 1280.00 pence to 1360.00 pence. Following these transactions, Craneware will hold 461,563 shares in treasury, leaving 35,080,606 ordinary shares in issue, which represents the total voting rights.

Disclaimer*

Craneware plc

01 April 2026

1 April 2026

Craneware plc

("Craneware" or the "Company")

Transaction in Own Shares

Craneware (AIM: CRW.L), a leader in healthcare financial performance solutions, announces today it has purchased the following number of its Ordinary Shares of 1 pence each through Investec Bank plc ("Investec") in the period from 24 March 2026 to 30 March 2026.

The table below contains detailed information about the purchases made as part of the buyback programme which was announced by the Company on 16 March 2026 (the "Programme").

Date	Venue	Volume-weighted average price (p)	Aggregated volume	Lowest price per share (p)	Highest price per share (p)
24 March 2026	AIMX	1328.7630	32,201	1310.0000	1343.3500
24 March 2026	XLON	1325.1859	7,799	1305.0000	1340.0000
25 March 2026	AIMX	1330.8239	22,090	1320.0000	1335.0000
25 March 2026	XLON	1330.7027	13,947	1320.0000	1350.0000
26 March 2026	AIMX	1337.9743	17,076	1320.0000	1360.0000
26 March 2026	XLON	1342.6037	11,595	1320.0000	1360.0000
27 March 2026	AIMX	1328.4879	22,255	1324.1900	1337.5000
27 March 2026	XLON	1330.2513	12,832	1320.0000	1350.0000
30 March 2026	AIMX	1292.2316	19,017	1280.0000	1314.0000
30 March 2026	XLON	1294.4535	14,921	1280.0000	1325.0000

The Company intends to hold the purchased shares in Treasury.

Following the above transactions, the Company will hold 461,563 Ordinary Shares in Treasury and has 35,080,606 Ordinary Shares in issue (excluding Treasury shares).

The figure of 35,080,606 represents the total voting rights in the Company and may be used by shareholders as the denominator for calculating whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Individual Transactions

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014 as it forms part of UK law, a full breakdown of the individual trades made by Investec on behalf of the Company as part of the buyback programme is attached to this announcement.

http://www.rns-pdf.londonstockexchange.com/rns/9433Y_1-2026-3-31.pdf

For further information please contact:

Craneware plc	+44 (0)131 550 3100
Keith Neilson, CEO
Craig Preston, CFO

Alma Strategic Communications	+44 (0)20 3405 0205
Caroline Forde, Kinvara Verdon, Louisa El-Ahwal	craneware@almastrategic.com

About Craneware

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in healthcare financial and operational transformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus^® cloud ecosystem unifies data, revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance, improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster - that simplify the complexities of healthcare finance and operations. What sets us apart is our unique combination of deep healthcare expertise and engineering excellence, positioning us as a strategic partner rather than just a technology provider. The Craneware Group empowers healthcare organizations to achieve sustainable financial success while delivering better outcomes for the communities they serve - today and in the future. Together, we are transforming the business of healthcare.

Learn more at www.thecranewaregroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END